Soligenix, Inc. (SNGX)


OTC BB - OTC BB Delayed Price. Currency in USD
0.83+0.03 (+3.62%)
At close: 3:59 PM EDT
People also watch:
FCSCSYNOGENTPIVAPHB
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.85
Prev Close0.80
Bid0.00 x
Ask0.00 x
Day's Range0.78 - 0.85
52wk Range0.44 - 1.44
1y Target EstN/A
Market Cap28.11M
P/E Ratio (ttm)-13.37
Beta0.06
Volume95,291
Avg Vol (3m)74,517
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire10 days ago

    Soligenix to Present at 2016 Aegis Growth Conference

    PRINCETON, N.J., Sept. 15, 2016 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Christopher J. Schaber, PhD, President and Chief Executive Officer, has been invited to present a company overview at the 2016 Aegis Growth Conference on Wednesday, September 21, 2016 at 9:30 a.m. PDT in Room 4. The conference will be held at the Encore at Wynn Las Vegas in Las Vegas, Nevada. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

  • Zacks Small Cap Research13 days ago

    Soligenix (SNGX) and SciClone (SCLN) Establish Regional Licensing Agreement for SGX942, a Novel Product Candidate for Oral Mucositis

    Earlier today (Sept. 12, 2016), Soligenix (SNGX) and SciClone Pharmaceuticals (SCLN), announced that the companies have entered into an exclusive license agreement for SGX942 (dusquetide), Soligenix’ lead candidate for the treatment of oral mucositis in patients with head and neck cancer. The agreement grants rights to SciClone to develop, promote, market, distribute and sell SGX942 in greater China area including the People's Republic of China, Hong Kong and Macau, as well as Taiwan, South Korea and Vietnam. This exclusive agreement builds on an existing collaboration between the two companies, in which SciClone provided its complete oral mucositis clinical and regulatory data library to Soligenix in exchange for certain, previously undisclosed, commercialization rights to SGX942 in the Greater China market.

  • PR Newswire13 days ago

    Soligenix and SciClone Establish Regional Licensing Agreement for SGX942, a Novel Product Candidate for Oral Mucositis

    PRINCETON, N.J. and FOSTER CITY, Calif., Sept. 12, 2016 /PRNewswire/ -- Soligenix, Inc. (SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, and SciClone Pharmaceuticals, Inc. (SCLN), a US-based China-focused specialty pharmaceutical company, announced today that the companies have entered into an exclusive license agreement granting rights to SciClone to develop, promote, market, distribute and sell SGX942 (dusquetide), a novel, first-in-class therapy being developed for the treatment of oral mucositis in patients with head and neck cancer. The licensing agreement includes the People's Republic of China, including Hong Kong and Macau, as well as Taiwan, South Korea and Vietnam (the "Territory").